RIOMET Stays on Shelves: FDA Greenlights Diabetes Med Continuity
Published Date: 3/13/2025
Notice
Summary
The FDA says RIOMET oral solution (metformin) hasn’t been pulled from the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they follow the rules. Patients and drug makers can keep counting on this medicine without any sudden changes or costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generics Can Still Be Approved
The FDA found that RIOMET (metformin hydrochloride) Oral Solution, 500 mg/5 mL has not been withdrawn for safety or effectiveness. Because of that, the FDA will continue to approve abbreviated new drug applications (ANDAs) that refer to this product as long as they meet legal and regulatory requirements.
Patients Can Rely on Drug Availability
The FDA determined RIOMET (metformin hydrochloride) Oral Solution, 500 mg/5 mL was not withdrawn for safety or effectiveness, and it will not begin procedures to withdraw approvals of ANDAs that refer to this drug. You (patients who use this medicine) can expect continued access and stability for this product without sudden regulatory withdrawal.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10614 — Color Additive Petition from Environmental Defense Fund, et al.; Request To Amend the Color Additive Regulations To Remove the Solvents Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period
The FDA is reopening the comment period on a petition from the Environmental Defense Fund and others to remove three harmful solvents—ethylene dichloride, methylene chloride, and trichloroethylene—from color additive rules. This change affects companies using these solvents in color additives and aims to make products safer. Comments are open until June 29, 2026, giving everyone a chance to share new info before any final decisions.
2026-10621 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Suturing Device for Altering Gastric Anatomy for Weight Loss
The FDA is officially classifying the endoscopic suturing device for weight loss as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative tool faster and ensures it’s safe and effective. The new rules took effect on May 28, 2026, and could save time and money for makers and users alike.
2026-10603 — Challenges and Solutions in Lot-Level Food Traceability; Public Meeting and Request for Comments
The FDA is hosting a virtual meeting on June 15, 2026, to talk about how to better track food by its lot number, making food safer and easier to trace. This affects food producers, sellers, and anyone involved in food safety, with a chance to suggest flexible ways to follow the rules. Comments on the ideas are open until July 15, 2026, so get involved and help shape the future of food tracking!
2026-10615 — Food Additive Petition From Environmental Defense Fund, et al.; Request To Amend the Food Additive Regulations To Remove the Solvents Benzene, Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period
The FDA is reopening the comment period on a petition from the Environmental Defense Fund and others to remove four harmful solvents—benzene, ethylene dichloride, methylene chloride, and trichloroethylene—from food additive rules. This change affects food makers who use these solvents and aims to make our food safer. Comments are open until June 29, 2026, giving everyone a chance to share new info before any costly changes happen.
2026-10479 — Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661
The FDA just announced that certain estrogen-androgen combo drugs, like Syntest D.S. and Syntest H.S., aren’t proven effective and can’t be sold unless they have official approval. This affects drug makers and sellers who must stop interstate shipments of these products by June 26, 2026. If you’re involved, it’s time to get compliant or say goodbye to these meds on the market!
2026-10372 — Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
The FDA wants your thoughts on how they collect info about making custom human drugs under special rules (Sections 503A and 503B). This affects pharmacies and drug makers who mix medicines just for patients. You’ve got until July 27, 2026, to share your comments—no cost changes yet, just a chance to help shape the paperwork process!
Previous / Next Documents
Previous: 2025-04019 — Information Collection; Certain Federal Acquisition Regulation Part 32 Requirements
The DoD, GSA, and NASA want to keep collecting certain info about government contracts for three more years, and they’re asking the public if this is still useful and not too much work. This affects businesses and folks involved in federal contracts, with no new costs but a chance to share feedback before July 31, 2025. It’s all about making sure the paperwork stays smart and easy!
Next: 2025-04021 — Issuance of Priority Review Voucher; Rare Pediatric Disease Product; Gomekli (mirdametinib)
The FDA just gave SpringWorks Therapeutics a special priority review voucher for their rare pediatric disease drug, Gomekli (mirdametinib), approved on February 11, 2025. This voucher speeds up the review of future drug applications, helping get important medicines to kids faster. Companies can use or sell these vouchers, which can save time and money in drug approval processes.